A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

PI: Frank A. Vicini


  • Lung Cancer


Michigan: Maria Pappas (248) 553-0606


  • Lung cancer

Primary Objective:
To determine whether the 12-month intracranial relapse rate following HA-PCI is non-inferior compared to the rate following PCI for patients with SCLC. To determine whether HA-PCI reduces the likelihood of 6-month deterioration from baseline in HVLT-R delayed recall compared to the PCI for patients with SCLC.

Patient Population:
Histologic proof or unequivocal cytologic proof (fine needle aspiration, biopsy or two positive sputa) of SCLC within 250 days prior to Step 1 registration; Zubrod performance status 0-2; Patients who are primary English or French speakers are eligible.